Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Change in Accured Expenses (2022 - 2025)

Coya Therapeutics (COYA) has disclosed Change in Accured Expenses for 4 consecutive years, with $849207.0 as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 4110.61% to $849207.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, up 173.41% year-over-year, with the annual reading at $1.1 million for FY2025, 173.41% up from the prior year.
  • Change in Accured Expenses hit $849207.0 in Q4 2025 for Coya Therapeutics, up from -$1.2 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.7 million in Q4 2023 to a low of -$1.3 million in Q1 2023.
  • Historically, Change in Accured Expenses has averaged $81631.7 across 4 years, with a median of $177596.5 in 2022.
  • Biggest five-year swings in Change in Accured Expenses: plummeted 875.4% in 2023 and later soared 4110.61% in 2025.
  • Year by year, Change in Accured Expenses stood at $102751.0 in 2022, then surged by 1567.72% to $1.7 million in 2023, then plummeted by 101.24% to -$21174.0 in 2024, then skyrocketed by 4110.61% to $849207.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for COYA at $849207.0 in Q4 2025, -$1.2 million in Q3 2025, and $1.0 million in Q2 2025.